SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
Tap a square to watch top doctors answer your top questions. Be sure to watch all the videos to get the full SPRAVATO® story, including safety information.
Tap a square to watch top doctors answer your top questions.
Be sure to watch all the videos to get the full SPRAVATO® story, including safety information.
What is treatment-resistant depression?
What makes SPRAVATO® different from oral antidepressants?
What can I expect at my first treatment?
What might a treatment center look like?
What does SPRAVATO® treat? What are the side effects?
Why is there an observation period after taking SPRAVATO®?
How often will I take SPRAVATO®?
How soon might I see improvement with SPRAVATO®?
What success have you seen with SPRAVATO®?
Watch this video on the SPRAVATO® Important Safety Information
Studied in adults with treatment-resistant depression.*
Nasal spray you self-administer under the supervision of a healthcare provider.
Taken with
an oral antidepressant.
Greater reduction of depressive symptoms at four weeks‡ (compared to those who received a placebo and oral antidepressant).
Tell your healthcare provider if you have a history of drug or alcohol abuse.
After you take SPRAVATO®, a healthcare provider will monitor you for at least two hours during the observation period for possible serious side effects, including feeling sleepy (sedation or loss of consciousness), feeling disconnected from yourself, your thoughts, feelings and things around you (dissociation), breathing problems (respiratory depression and respiratory arrest), and increased blood pressure.
* In clinical trials, treatment-resistant depression was diagnosed in adults who were struggling with major depressive disorder and had not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode.
† Along with an oral antidepressant.
‡ In clinical trials of adults who took SPRAVATO® and an oral antidepressant compared to those who received a placebo and an oral antidepressant. Based on an overall score on a standardized rating scale.
